4B70 Stock Overview
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Antibe Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.19 |
| 52 Week High | CA$0.81 |
| 52 Week Low | CA$0.10 |
| Beta | 0.12 |
| 1 Month Change | -34.72% |
| 3 Month Change | -72.55% |
| 1 Year Change | -45.03% |
| 3 Year Change | -93.14% |
| 5 Year Change | -91.42% |
| Change since IPO | -95.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4B70 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -1.2% |
| 1Y | -45.0% | -28.2% | 1.8% |
Return vs Industry: 4B70 underperformed the German Pharmaceuticals industry which returned -27% over the past year.
Return vs Market: 4B70 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 4B70 volatility | |
|---|---|
| 4B70 Average Weekly Movement | 32.5% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4B70's share price has been volatile over the past 3 months.
Volatility Over Time: 4B70's weekly volatility has increased from 17% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 11 | Dan Legault | www.antibethera.com |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company’s pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain.
Antibe Therapeutics Inc. Fundamentals Summary
| 4B70 fundamental statistics | |
|---|---|
| Market cap | €10.65m |
| Earnings (TTM) | -€12.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 4B70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4B70 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$18.24m |
| Earnings | -CA$18.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4B70 perform over the long term?
See historical performance and comparison